Illumina (NASDAQ:ILMN) Earns Overweight Rating from Piper Sandler

Illumina (NASDAQ:ILMN)‘s stock had its “overweight” rating restated by equities research analysts at Piper Sandler in a research note issued to investors on Monday,Benzinga reports. They presently have a $225.00 target price on the life sciences company’s stock, up from their prior target price of $200.00. Piper Sandler’s target price would suggest a potential upside of 11.48% from the stock’s previous close.

Other analysts have also issued research reports about the stock. Sanford C. Bernstein reiterated a “market perform” rating and set a $215.00 price target on shares of Illumina in a research report on Friday. TD Cowen raised their target price on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a report on Friday. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Citigroup restated a “sell” rating on shares of Illumina in a research note on Monday. Finally, JPMorgan Chase & Co. upped their price objective on shares of Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $177.82.

Illumina Stock Performance

NASDAQ ILMN traded down $3.27 during trading on Monday, reaching $201.83. The company’s stock had a trading volume of 677,179 shares, compared to its average volume of 1,894,287. The firm has a 50 day moving average price of $176.70 and a 200 day moving average price of $147.25. Illumina has a 12 month low of $88.00 and a 12 month high of $207.00. The firm has a market capitalization of $30.54 billion, a price-to-earnings ratio of 37.72, a price-to-earnings-growth ratio of 2.94 and a beta of 1.47. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts anticipate that Illumina will post 5.37 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares in the company, valued at $3,456,500.81. This trade represents a 3.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the sale, the senior vice president directly owned 15,056 shares in the company, valued at $2,093,386.24. The trade was a 4.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,003,769 shares of company stock worth $155,710,908 over the last quarter. 2.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Illumina

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ILMN. Elyxium Wealth LLC acquired a new position in shares of Illumina in the 4th quarter worth approximately $25,000. Creative Capital Management Investments LLC boosted its position in shares of Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. bought a new position in shares of Illumina during the 4th quarter worth approximately $26,000. Laurel Wealth Advisors LLC bought a new position in Illumina during the fourth quarter worth $26,000. Finally, Elevation Wealth Partners LLC grew its holdings in Illumina by 52.5% in the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after purchasing an additional 84 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.